Rezolute's rare disease drug fails main goal in late-stage trial

Core Insights - Rezolute's experimental drug for a rare condition causing dangerously low blood sugar did not meet its primary endpoint in a late-stage clinical trial [1] Company Summary - Rezolute announced the failure of its drug in a late-stage study, which is significant for the company's pipeline and future prospects [1]